skip to Main Content
 

Director Deals: CentralNic, Braveheart, Ncondezi Energy

*
  • CentralNic non-exec buys 17,015 shares
  • Non-exec buys 7.3m Ncondezi Energy shares
  • Braveheart Investments director buys 350,000 shares
  • CFO buys 550,000 Digitalbox shares
  • Induction Healthcare Chair buys 266,667 shares

CentralNic [LON:CNIC] non executive director Max Royde has purchased on 16th January 17,015 shares at an average price of £1.544817 per share for a total cost of £26,271 through Kestrel Opportunities, a company Mr Royde has a beneficial interest in.

The AIM-listed IT company operating in digital advertising and domain name management announced its results back in November. The company reported revenue had increased by 88% to USD526.7m (GBP442.1m), against USD280.6m for the nine months to end-September 2021 but it is in the expansion of their Online Marketing division where the business sees a much bigger market with significant growth potential.

At close of trading on 16th January, shares were priced at 155p, a return of -0.96% on the year to date and +13.6% over the last 12 months.


Ncondezi Energy [LON:NCCL] non-Executive Director Scott Fletcher has purchased an aggregate of 7,256,555 shares in the company at an average price of 0.77p for a total cost of £55,875 and after market close on 16 January 2023 issued a conversion notice of approximately £83,129 of outstanding convertible loans, together with interest, held by him. The loan is due to be converted at a 25% discount to the previous 30 day Volume Weighted Average Price and the company is reviewing this in the best interests of shareholders.

The AIM-listed Mozambican power developer has spent the last year restructuring expensive debt to continue operating and expects to begin mining this year.

At close of trading on 16th January, shares were priced at 0.83p, a return of 30% year to date and 17% over the last 12 months.

Braveheart Investments [LON:BRH] Director Trevor Brown purchased 350,000 shares on 13th January at a price of £0.08 per share for a total cost of £28,000. The AIM listed UK-based private equity and venture capital company recently updated the market on Phasefocus and Paraytec, two companies that sit within the Group’s investment portfolio. The business is seeking further funding for Phasefocus to help its sales drive whilst Paraytec’s clinical study at the Sheffield Teaching Hospitals NHS Foundation Trust has been delayed with test results for the first phase now expected in February 2023, with the full analysis likely to be in April 2023.

Shares in Braveheart were priced at 9p, a return of -6.5% for the year to date and -57% for the last 12 months.

Digitalbox [LON:DBOX] Chief Financial Officer David Joseph has purchased 550,000 shares on 13th January at a price of 8p for a total cost of £44,000. The mobile-first digital media business which owns Entertainment Daily, The Daily Mash, The Tab and The Poke has recently issued a full year trading update saw EBITDA up on last year and in line with market guidance. Economic headwinds have seen revenue fall below market expectations amidst challenging conditions across the media industry but the group appears in good shape, sitting on a cash reserve of £2.8m.

Shares in Digitalbox at the close of play on 16th January were sitting at 8p, down 8.6% on the year to date and -30% over the last 12 months.

Induction Healthcare [LON:INHC] Executive Chair, Christopher Samler purchased 266,667 shares at 22.5p on 13 January 2023 at a total cost of £60,000. The AIM listed company is a leading digital health platform driving transformation of healthcare systems worldwide issues a half year report last month indicating that the rate of growth this year will be impacted by delays in the implementation of digitisation programmes whilst also citing the general political turmoil. The Group expects to see their opportunities to be maintained but suggests they are now more likely to conclude in the next financial year.

Shares in Induction Healthcare sat at 22.5p at the close of business on 16th January, up 1% on the year to date and -61% on the last 12 months.

Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

The Armchair Trader's 'How to' Guides

In-depth Reports

Detailed reviews of selected companies and investment trusts.

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
FP Markets
IG
Pepperstone
WisdomTree
CME Group
Back To Top